Neoadjuvant TAR-200 (intravesical gemcitabine) plus cetrelimab shows improved pathologic responses and MRD signal utility in cisplatin-ineligible MIBC: Primary SunRISe-4 analysis
Highlight
– In SunRISe-4, neoadjuvant TAR-200 (gemcitabine intravesical system) plus the PD‑1 antibody cetrelimab produced a pathologic complete response (pCR) rate of 38% and pathological overall response (pOR; ≤ypT1N0) of 53% in patients with cT2–T4a N0M0 muscle‑invasive bladder cancer (MIBC) who were ineligible for or refused cisplatin.
– Cetrelimab monotherapy yielded lower pCR (28%) and pOR (44%) rates; 1‑year recurrence‑free survival (RFS) was 77% with the combination versus 64% with monotherapy.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.